



GlycoEra AG Announces its Incorporation and Welcomes Ganesh Kaundinya as Inaugural Member of the Board of Directors

Schlieren, SWITZERLAND – January 5, 2021 – GlycoEra AG announced today its incorporation with the purpose of leveraging a proprietary glycoengineering platform to develop a pipeline of novel biologics for inflammatory disease, autoimmune disorder and immuno-oncology indications. The company has been founded as a product development-focused spin-out of LimmaTech Biologics AG and has obtained a world-wide exclusive license from LimmaTech to its CustomGlycan Platform and associated assets.

“We have established GlycoEra to unlock the full value of the CustomGlycan Platform by driving a range of product candidates toward clinical proof-of-concept,” stated Veronica Gambillara Fonck, PhD, CEO and co-founder of GlycoEra. “Based on our years of expertise in understanding the role glycans play in therapeutic development, we believe that our specialized glycoengineering team, with its proven track-record, will demonstrate the platform’s value and potential in producing new therapies.”

Amir Faridmoayer, GlycoEra’s Chief Scientific Officer and co-founder, added: “As the understanding of glycobiology and glycoimmunology increases, it is evident that glycans are essential for regulating different biological pathways in humans. The translation of this knowledge into effective therapeutics has been hampered due to the complexity of producing specific glycan structures with high homogeneity. GlycoEra’s CustomGlycan Platform enables us to precisely and selectively target specific glycan-mediated biological pathways to develop novel products for challenging diseases.”

GlycoEra is pleased to announce that biopharmaceutical veteran, Ganesh Kaundinya, PhD, a founder and most recently the Chief Operating Officer and Chief Scientific Officer of Momenta Pharmaceuticals (lately acquired by Johnson and Johnson), has joined as the first member of the company’s Board of Directors. He has extensive experience in biopharmaceutical company formation, growth, product development and commercialization.

Dr. Kaundinya commented: “I am looking forward to working closely with the newly-established GlycoEra team to unlock the power of the technology and support the company as they develop novel biological products targeting glycan-mediated biology for a range of indications.”

About GlycoEra AG

For further information, visit www.glycoera.com

Company contact:

GlycoEra AG

veronica.gambillara@glycoera.com

Phone: +41 44 733 85 75